Emerging Healthcare Solutions and ThromboVision complete due diligence process under new option agreement

Emerging Healthcare Solutions, Inc. (Pinksheets: EHSI) and ThromboVision have completed phase one of their due diligence process under their new option agreement. Emerging Healthcare solutions received ThromboVision’s financial forecasts on January 14^th and satisfactorily completed the forecast review today, enabling both parties to proceed. The purpose of the agreement with ThromboVision is to allow the parties to aggressively seek the establishment of business opportunities with ThromboVision’s new patented T-Guide® Platelet Function Analyzer, which is currently in regulatory clearance review.

“Successfully completing phase one allows us to move forward and shift our focus to potential business realities”

The new analyzer consists of a desktop instrument and a disposable test kit that can be located at doctor’s offices and could become a front line technology that could help prevent heart attacks, strokes and stent occlusions by directly analyzing a patient’s platelet status on-site. This new technology should enable doctors to directly measure platelet status as easily as measuring cholesterol. In the US, cardiologists and primary care physicians manage 80 million cardiovascular visits each year, with over 30 million of these patients on Aspirin or Plavix® platelet therapy.

“Successfully completing phase one allows us to move forward and shift our focus to potential business realities,” said Steven Price, Emerging Healthcare’s Senior Vice President for Business Development.

The emerging healthcare industry is expected to continue steady expansion, which could be beneficial to many cutting-edge companies such as Medicis (NYSE: MRX), Pharmacyclics (NASDAQ: PCYC), Vertex Pharmaceuticals (NASDAQ: VRTX) and Qiagen (NASDAQ: QGEN).